|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
|
acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Adult Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Adult Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High expression of miR-148a-5p targets (PHLDA2, LPCAT2 and AP1S3) and miR-148a-3p targets (SMA, ENDOD1 and UHMK1) was associated with poor prognosis of patients with PDAC.
|
29660218 |
2018 |
|
Becker Muscular Dystrophy
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
One locus on 1q23 (UHMK1, rs16863247, P=4.1×10(-7) for femoral neck BMD and P=3.2×10(-6) for total hip BMD) was a novel BMD signal.
|
27424934 |
2016 |
|
Brain Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Our results demonstrate the effectiveness of an aryloxazole moiety in targeting brain tumors and suggest KIST-G1 as a potent anti-glioblastoma agent.
|
31569420 |
2019 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Further, in vivo KIS gene silencing enhanced the antitumor activity of erlotinib in an orthotopic breast cancer xenograft model.
|
21045138 |
2010 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Childhood Diffuse Large Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Childhood Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Childhood Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
|
Congenital chromosomal disease
|
0.010 |
Biomarker
|
group |
BEFREE |
We analysed PAX5/BSAP expression by Northern and Western blotting in a panel of haematological tumour cell lines with other chromosome abnormalities in comparison with that of KIS-1.
|
9722295 |
1998 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 is the only known B-cell line derived from Ki-1-positive diffuse large cell lymphoma, and should be useful for defining the biological implications of Ki-1 antigen.
|
2852183 |
1988 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
When compared with six other DLCL cell lines lacking t(9;14)(p13;q32), the KIS-1 cell line showed an 11-fold overexpression of PAX-5 mRNA and a significantly reduced expression of the p53 gene, which is normally regulated by PAX-5.
|
8943844 |
1996 |
|
Diffuse Large B-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
KIS-1 cell line was established from a patient with diffuse large cell lymphoma of B-cell type carrying t(9;14).
|
9722295 |
1998 |
|
Glioblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
Glioblastoma Multiforme
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aid by the BBB-permeable properties, KIST-G1 (5 mg/kg) suppressed glioblastoma cell growth and migration almost completely in the brain of glioblastoma xenograft models by showing 98.2 ± 0.1% reduced tumor area compared with phosphate buffered saline (PBS)-injected control.
|
31569420 |
2019 |
|
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |
|
Leukemia, Myelocytic, Acute
|
0.010 |
Biomarker
|
disease |
BEFREE |
We showed that KIS mRNA expression was increased in primary leukemia specimens (acute myelogenous leukemia (AML); 37, myelodysplastic syndrome (MDS); 72, acute lymphoblastic leukemia (ALL); 23), and the mean ratios of KIS to G3PDH in AML, MDS and ALL specimens were 3.62+/-0.68, 3.27+/-0.73 and 3.17+/-0.58, respectively.
|
18384876 |
2008 |